Quretech bio Fördelningen i styrelsen är 100. The cost of antibiotic resistance to medical communities QureTech Bio AB (QTB), a pharmaceutical development company originating from Umeå University, proudly announces the appointment of three new board members at its Annual General Meeting held on May 25, 2023. Hilicon. “Our vision is to contribute to solving the global problem of Read our latest news, research and progress at Quretech Bio News. This strategic move is aimed at further enhancing QTB’s drug and business development. We address a significant unmet medical need by developing a new class of antibacterial agents that target antimicrobial resistance. The company is focused on finding innovative ways to target resistant bacterial infections, particularly those that are resistant to multiple drugs. Here’s the story behind. m. Kempestiftelserna representative joins the board of QureTech Bio . Protected Content. The cost of antibiotic resistance to medical communities QureTech Bio receives support from ENABLE-2. Read More QURETECH BIO Tvistevägen 48 907 36 UMEÅ QureTech Bio AB | 475 followers on LinkedIn. QureTech Bio AB - Org. Together with the company’s extremely competent employees, we now have a very interesting trip in front of us, where we seriously believe that the company can make a difference, “says Håkan Quretech Bio develops innovative antibiotics by stopping bacterial virulence with a first-in-class active substance. Business Management. The QTB team is also gearing up for the Umeågalan on March 21st, where they are nominated for “University Spin-Off of the Year”. Who is Quretech Bio. The approach is not to kill bacteria, but make them harmless – thus complementing existing treatments and making established antibiotic drugs more effective without causing resistance. Job Department. QureTech Bio AB (QTB) is a biotechnology company developing new solutions to combat disease-causing bacteria to tackle one of our times' greatest threats, antimicrobialhealth resistance (AMR). Alltid uppdaterat. Skip to content. Louis have received an $11 million grant from the National QureTech Bio is developing new drugs that either enhance the existing effects of antibiotics or disarm bacteria instead of killing them, thereby reducing the threat of resistance. All; Ranked; Organisation Names; Apps and Links. Showing 1 of 1 Employee Profiles. Malin Otmani. Details. Read More Professor Scott Hultgren, CSO of QureTech Bio, elected fellow of the National Academy of Inventors. Read More QureTech Bio expands workforce following major investment. QureTech Bio founders in major US investment to combat antibiotic resistance. 169 likes. The cost of antibiotic resistance to medical communities QURETECH BIO - THE NORDIC VOICE IN AMR-EUROPE. Förhoppningen är att QureTech Bio ska bidra till effektivare framtida behandlingar av infektionssjukdomar. The global market for antibiotics is estimated at USD 38 billion with USA, Europe and Japan representing 50%. · Erfarenhet: QureTech Bio AB · Utbildning: Uppsala University · Plats: Uppsala · 474 kontakter på LinkedIn. “We have recently secured significant new investment and so it feels like the perfect time for Helén to come in and develop our business even further,” says Fredrik Almqvist. Yijing Sun Hultgren. com (QureTech Bio), the project host. Bolaget hade då en omsättningstillväxt på 73. MetaCurUm Secures SEK 1 Million Grant for Umeå life science company QureTech Bio has received a SEK [] By quretech-cio | 2020-07-02T15:15:07+00:00 April 21st, 2020 | News | 0 Comments. Edit Contacts Section. 🌍 She is the sole Nordic representative on the board of BEAM Alliance, at QureTech Bio AB | 643 followers on LinkedIn. nummer: 5568109465. 0 % män (6), 0. We are also seeking collaboration partners for further development of the chlamydia and tuberculosis projects. Scott Hultgren, CSO of QureTech Bio and Helen L. QureTech Bio AB | LinkedIn 팔로워 778명 | Develops new alternatives to combat antibiotic resistance | QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. The company’s lead program is focused on developing a new class of antibiotics, called GmPcides, that are effective against multidrug-resistant Gram QURETECH BIO - THE NORDIC VOICE IN AMR-EUROPE. The Umeå-based company now receives support from the Swedish Research Council’s ENABLE-2 in collaboration with Vinnova. Develops new alternatives to combat antibiotic resistance | QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. Prenumerera på vårt nyhetsbrev. The global market for antibiotics is estimated at USD 38 billion QureTech Bio AB (QTB) is a biotechnology company developing new solutions to combat disease-causing bacteria to tackle one of our times' greatest threats, antimicrobialhealth QureTech Bio is a Swedish pharmaceutical development company that addresses a significant medical need by developing a new class of antibacterial agents that target antimicrobial resistance. Page load link. QureTech Bio AB | 721 abonnés sur LinkedIn. About Quretech Bio: Quretech Bio is a Swedish pharmaceutical development company that addresses a significant medical need by developing a new class of antibacterial agents that target antimicrobial resistance. At the Annual General Meeting of QureTech Bio AB (QTB), [] By quretech-cio | 2023-05-29T09:06:38+00:00 May 29th, 2023 | Uncategorized | 0 Comments. 3%. The cost of antibiotic resistance to medical communities QureTech Bio AB | 714 followers on LinkedIn. Foto/collage: Quretech Bio QureTech Bio har utvecklat nya substansklasser med olika verkningsmekanismer som dels kan fungera som traditionella antibiotika, förstärka effekten av befintliga antibiotika eller avväpna bakterier istället för att döda dem. Om Quretech Bio: Quretech Bio is a Swedish pharmaceutical development company that addresses a significant medical need by developing a new class of QureTech Bio expands workforce following major investmentApril, 2021Umeå-based pharmaceutical development [] By quretech-cio | 2024-07-04T08:06:35+00:00 April 16th, 2021 | News | 0 Comments. QureTech Bio is a Swedish pharmaceutical development company that addresses a significant medical need by developing a new class of antibacterial a gents that target antimicrobial resistance. Yijing has over a decade of experience in finance. Sed rutrum quam tincidunt, lobortis arcu non “QureTech Bio fits well into our strategy of investing in prospective global game-changers with world-leading researchers and access to potential billion SEK markets. Further pharmaceutical development and clinical trials will be necessary before GmPcides could By quretech-cio | 2019-12-12T15:23:43+00:00 January 31st, 2015 | News | 0 Comments. Reflection from QureTech Bio’s CEO. Jag ser fram emot att arbeta med teamet, styrelsen och våra partners för att föra företagets pipeline till klinisk fas och leverera nya terapier till behövande QureTech Bio AB har 5 anställda och gjorde ett resultat på -5,372 KSEK med omsättning 2,521 KSEK under 2023. View . Tomorrow CEO Helén Fält will highlight the possibilities and challenges for small companies like QureTech Bio AB in discussions of Life Science arena in Umeå. 🌍 She is the sole Nordic representative on the board of BEAM Alliance, at the forefront of promoting antimicrobial research and development in Europe. These features include embedding content such as videos or sharing About QureTech Bio: QureTech Bio is a Swedish pharmaceutical development company that addresses a significant medical need by developing a new class of antibacterial agents that target antimicrobial resistance. Where is QureTech Bio's headquarters? QureTech Bio's headquarters is located at Tvistevagen 48, Umea. Louis has been elected as a member of QureTech Bio AB | 475 followers on LinkedIn. The cost of antibiotic resistance to medical communities QureTech Bio has 2 current employee profiles, including Co-Founder Jörgen Johansson. The cost of antibiotic resistance to medical communities QureTech Bio will continue the development of PS757 and other GmPcides and potentially bring them to market. QureTech Bio is a part of. The company’s lead program is focused on developing a new class of antibiotics, called GmPcides, that are effective against multidrug resistant Gram QureTech Bio har utvecklat nya substansklasser med olika verkningsmekanismer som dels kan fungera som traditionella antibiotika, förstärka effekten av befintliga antibiotika eller avväpna QureTech Bio have been nominated as ”University Spin-off of the Year” at the local business gala, Umeågalan. Researchers at Washington University School of Medicine in St. The cost of antibiotic resistance to medical communities The field has turned to combinatory treatments, which could reach the market faster,” explains Fredrik Almqvist, CEO of www. E-mail: markus. Read more at QureTech Bio’s web. It is Nordiska Centrumhus that shares the Quretech Bio vision regarding new drugs against infectious diseases and antibiotic resistance by backing company growth in the region, reports Umeå Biotech Incubator. QureTech Bio AB (QTB) is a pharmaceutical development company with a focus on developing new solutions to combat disease-causing bacteria and thereby contribute with new alternatives to one of our times’ greatest threats to modern healthcare, antibiotic resistance. QureTech Bio AB får stort stöd för fortsatt utveckling av nya antibiotika! Stödet kommer från Vetenskapsrådet storsatsning ENABLE-2 som i samarbete med Vinnova även ger små och medelstora företag QureTech Bio AB | 554 følgere på LinkedIn. QureTech Bio is pushing for increased funding for the ongoing drug development. The cost of antibiotic resistance to medical communities QureTech Bio AB | 475 followers on LinkedIn. Kempestiftelserna is two QureTech Bio are addressing a significant unmet medical need by developing a new class of antibacterial agents that target antimicrobial resistance. Adept at using a range of organic chemistry techniques and data analysis tools to design and create new pharmaceutically active molecules to combat bacterial QureTech Bio AB 685 followers 1y Report this post We proudly share the news that one of our founders, professor Scott Hultgren at Washington University in St. Edit Details Section. We keep fingers crossed! 🤞 📖 QureTech Bio is a pharmaceutical development company whose vision is to develop a new antibiotic class to combat infectious diseases and the of antibiotic QureTech Bio AB | ٧٨١ من المتابعين على LinkedIn. Antalet anställda är oförändrat sedan året innan. QureTech Bio is currently focusing on the lead program, GmPcides for healthcare associated infections, and the company’s vision is to contribute to more effective treatments for infectious diseases. Ansvarig är Lars Markus Thor 53 år. Welcome to contact us for more information about partnership opportunities. Stoever Professor of Molecular Microbiology at Washington University School of Medicine in St. The cost of antibiotic resistance to medical communities Fredrik Almqvist, Chief Chemist at QureTech Bio, yesterday received the precious Nordblad-Ekstrand medal for his development of small molecules that disarm bacteria and effect amyloid formation. quretech. QureTech Bio develops new synthetic antibacterial agents that address significant medical need in infectious disease. com Page 1 (2) QureTech Bio appoints three new board members . View All Contacts . The compounds are new small molecule chemical entities from a well-developed chemical platform with excellent synthetic availability and desirable drug With this financial support, QureTech Bio will be able to accelerate its research and development efforts of novel antibiotic treatments and bringing life-saving treatments closer to those who need them most. Stoever Professor of Molecular Microbiology and director of the Center for Women’s Infectious Disease Research at the School of Medicine at Washington University in St. QureTech Bio har utvecklat nya substansklasser med olika verkningsmekanismer som dels kan fungera som traditionella antibiotika, förstärka effekten av befintliga antibiotika eller avväpna bakterier istället för att döda dem. IN THE RIGHT PLACE AT THE RIGHT TIME QureTech Bio AB | 783 följare på LinkedIn. 09 Dec 2024 . Visa Ulf Björklunds profil på LinkedIn, ett yrkesnätverk med 1 miljard medlemmar. The company has developed new substances with various mechanisms that can act as traditional antibiotics, enhance the effect of existing antibiotics or disarm bacteria instead of QureTech Bio AB (QTB) är ett läkemedelsutvecklingsföretag med fokus på att utveckla nya lösningar för att bekämpa sjukdomsframkallande bakterier och därmed bidra med nya alternativ till en QURETECH BIO - THE NORDIC VOICE IN AMR-EUROPE. 5 million from the Swedish Research Council, SEK 8 million from the Erling Persson Family Foundation and SEK 2. Markus Thor on his new assignment: "I am honored and excited to join QureTech Bio, a company that is at the forefront of developing new and much needed solutions for the global health challenge of antimicrobial resistance. Lorem ipsum dolor sit amet, consectetur adipiscing elit. The cost of antibiotic resistance to medical communities QureTech Bio AB | 763 followers on LinkedIn. Together they complement eachother and add valuable competence within drug- and business development. Telephone: +46 73-520 40 35 Web: www. Prenumerera. QureTech Bio AB | 543 seguidores en LinkedIn. QureTech Bio is a Swedish pharmaceutical development company that addresses a significant medical need by developing a new class of antibacterial agents that target antimicrobial resistance. Louis [] By quretech-cio | 2021-05-21T13:41:52+00:00 May 21st, 2021 | News | 0 Comments. Chairman at Stayble Therapeutics AB · After more than 30 years of experience in the pharmaceutical industry (mainly in management positions) I QureTech Bio founders in major US investment to combat antibiotic resistance. Biotech Life Science Companies. QureTech Bio AB | 739 followers on LinkedIn. About Quretech Bio: Quretech Bio is a Swedish pharmaceutical development company that addresses a significant medical need by developing a new class of QureTech Bio AB | 778 followers on LinkedIn. The cost of antibiotic resistance to medical communities QureTech Bio AB (QTB) is a pharmaceutical development company with a focus on developing new solutions to combat disease-causing bacteria and thereby contribute with new alternatives to one of our times’ greatest threats to modern Todays issue of BioCentury has a feature story about QureTech Bio. The cost of antibiotic resistance to medical communities QureTech Bio AB | 539 Follower:innen auf LinkedIn. QureTech Bio’s vision is to develop first-line medicines to combat infectious diseases and the occurrence of antibiotic resistance QureTech Bio is currently working on three projects aimed at treating tuberculosis, chlamydia and other infections caused by antibiotic-resistant bacteria. This is done either by a direct antimicrobial effect or by potentiating existing antibiotics. 1 email found . Louis Inventors: Christina Leigh Stallings, Gregory Alexander Harrison, Fredrik Almqvist, Souvik Sarkar Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis QureTech Bio AB | ٧٧٠ من المتابعين على LinkedIn. How much did QureTech Bio raise? QureTech Bio raised a total of $16. The cost of antibiotic resistance to medical communities QureTech Bio AB | 557 seguidores en LinkedIn. QureTech Bio AB | 761 followers on LinkedIn. Quretech Bio AB är verksam inom annan naturvetenskaplig och teknisk forskning och utveckling och hade totalt 5 anställda 2023. We got a great impression of the company and its founders and are now looking forward to a long-term collaboration together,” says Erik Gozzi, Co-Founder and CEO of Nascent Helén Fält, CEO of QureTech BIO, is now a Board Member of the BEAM Alliance. The cost of antibiotic resistance to medical communities QureTech Bio, which is located at the Umeå Biotech Incubator (UBI), wants to combat this by developing new drugs that either enhance the effect of existing antibiotics or that disarm bacteria instead of killing them, thus reducing resistance development. Headquarters Regions European Union (EU), Nordic Countries, Scandinavia; Founded Date Jan 1, 2014; QureTech Bio AB www. ”This investment will enable us to accelerate our development programs. QureTech Bio is actively seeking investors and collaboration partners to enable development and commercialization of the company’s pipeline programs. QureTech Bio announces prestigious investment from Kempestiftelserna. What is QureTech Bio's latest funding round? QureTech Bio's latest funding round is Unattributed VC - II. QureTech Bio AB | ۷۷۸ دنبال کنندگان در لینکدین Develops new alternatives to combat antibiotic resistance | QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. This is done either by a QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. To change the settings and see more detailed information see our Settings Allow all cookies Third Party Embeds This website uses cookies and third party services. Researchers from Quretech Bio AB (Quretech Bio) in Umeå, who were awarded a research grant of approximately SEK 25 million in the summer, have been awarded additional funding of just over SEK 17 million this autumn (made up of SEK 7. The cost of antibiotic resistance to medical communities QureTech Bio AB | 557 Follower:innen auf LinkedIn. com +46 70-397 90 97. The cost of antibiotic resistance to medical communities QURETECH BIO SECURES MULTI-MILLION INVESTMENT FROM KEMPESTIFTELSERNA QureTech Bio AB has received a capital injection of SEK 14 million from Kempestiftelserna and the company’s largest Tre affärsgrenar utvecklas parallellt i Quretech Bio. CEO at QureTech Bio AB 1 Jahr Diesen Beitrag melden We have several activities planned for future development and I am really trilled to welcome the new board members Ulf Björklund, Lennart Hansson and Yijing Sun Hultgren. Vid senaste bokslut 2023 hade företaget en omsättningsförändring på 73. QureTech Bio AB. One of the company's founders is Professor Fredrik Almqvist, who believes it is necessary to find new ways to eliminate pathogenic QureTech Bio AB | 705 followers on LinkedIn. January, 2022. Bolaget är ett aktiebolag som varit aktivt sedan 2010. The cost of antibiotic resistance to medical communities Om Quretech Bio AB. 1) As a board member of the BEAM Alliance, could you explain its function? QureTech Bio AB | 477 من المتابعين على LinkedIn. QureTech Bio. The cost of antibiotic resistance to medical QureTech Bio AB | 480 followers on LinkedIn. com. almqvist@quretech. Quretech Bio. Quretech's research is seen as critical in addressing the QureTech Bio AB | 697 volgers op LinkedIn. QURETECH BIO - THE NORDIC VOICE IN AMR-EUROPE. The cost of antibiotic resistance to medical communities The compound has been patented and licensed to QureTech Bio, a company in which the researchers have a stake. 🌍 She is the sole Nordic representative on the board of BEAM Alliance, at The AMR Industry Alliance brings together biotech, diagnostics, generics and research-based pharmaceutical companies, to drive and measure industry progress to curb antimicrobial resistance. I look forward to working with the team, the board, and our partners to advance the company's pipeline into the –QureTech Bio är ett företag i framkant när det gäller att utveckla nya och mycket behövda lösningar för den globala hälsoutmaningen med antimikrobiell resistens. Quretech Bio’s vision is to develop first-line medicines to combat infectious diseases and the occurrence of antibiotic resistance QureTech Bio AB | 687 followers on LinkedIn. The cost of antibiotic resistance to medical communities Quretech Bio, which operates from the Umeå Biotech Incubator, wants to combat this problem by developing new medicines that either disarm bacteria instead of killing them or amplifies the effect of existing antibiotics. March 23, 2022. 🌍 She is the sole Nordic representative on the board of BEAM Alliance, at When was QureTech Bio founded? QureTech Bio was founded in 2010. QureTech Bio has developed new classes of substances with different mechanisms of action that can either function as traditional antibiotics, enhance the effect of existing antibiotics or disarm bacteria instead of killing QureTech Bio AB 765 followers 1y Report this post Our CEO summaries year 2022 and looking ahead for 2023! Helén Fält Commercial Manager at APL 1y As we enter a new year it is always good to Umeåbolaget Quretech Bio, som utvecklar nya antibiotika och infektionsbehandlingar, har utsett Markus Thor till ny vd. Caparon, Hultgren and Almqvist have patented the compound used in the study and licensed it to a company, QureTech Bio, in which they have an ownership stake, with the expectation that they will be able to collaborate with QureTech Bio AB | ৭৬২ লিংকডইনে ফলোয়ার। Develops new alternatives to combat antibiotic resistance | QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. QureTech Bio's vision is to develop first-line medicines to combat infectious diseases and the occurrence of antibiotic resistance, establishing itself as QureTech Bio AB is a biotechnology company developing new solutions to combat disease-causing bacteria to tackle one of our times’ greatest health threats, antimicrobial resistance (AMR). The cost of antibiotic resistance to medical communities QureTech Bio AB | 641 followers on LinkedIn. He was previously elected to the National Academy of Medicine Scott Hultgren, co-founder of QureTech Bio, Helen L. A total of SEK 14 million was invested in the company by Kempestiftelserna along with the company’s largest shareholder Nascent Invest. The cost of antibiotic resistance to medical Chief Operating Officer at QureTech Bio AB · Erfarenhet: QureTech Bio AB · Plats: Holmsund · 325 kontakter på LinkedIn. com . Edit Employee Profiles Section. QureTech Bio develops new first-in-class antibacterial agents to combat infectious diseases and the occurrence of antibiotic resistance. Louis, has been elected fellow of the National Academy of Inventors, the highest professional distinction accorded to academic inventors. Quretech Bio har idag tre huvudprojekt som riktar sig mot behandling av tuberkulos, klamydia och infektioner orsakade av antibiotikaresistenta bakterier. Hemsida Tillbaka till medlemmar. The cost of antibiotic resistance to medical communities QureTech Bio is a pharmaceutical development company whose vision is to, through its world-leading research, develop a new antibiotic class to combat infectious diseases and the occurrence of antibiotic resistance. Read More Professor Scott Hultgren, co-founder of QureTech Bio, elected member of the American Academy of QureTech Bio AB | 524 followers on LinkedIn. thor@quretech. Our approach to treat bacterial infections with virulence blockers for treatment of Chlamydia and Tuberculosis are described. 96M. 3 %. Additionally, Quretech Bio, a Swedish biotech company, has secured significant funding to advance its development of new antibiotics. QureTech Bio Looks to the Future With Appointment of New [] By quretech-cio | 2024-07-04T08:09:24+00:00 January 25th, 2021 | Uncategorized | 0 Comments. Quretech Bio AB omsatte 2 521 000 kr senaste räkenskapsåret (2023). Assignees: Quretech Bio AB, Washington University in St. The compounds are new small molecules from a well-developed QureTech Bio was founded by leading researchers from Umeå University, Sweden and Washington University, St Louis, USA with the aim to develop new antibiotics. QureTech Bio’s vision is to develop first-line drugs to combat infectious diseases and the occurrence of antibiotic resistance. QureTech Bio, a biotechnology company developing novel antibiotics and anti-infectives, today announced that Markus Thor has been appointed as the new Chief Executive Officer, effective Umeå-based QureTech Bio is developing new solutions to combat disease-causing bacteria to tackle antimicrobial resistance (AMR). The company develops antibacterial agents containing several distinct classes of small molecules that target different infectious diseases through research, enabling users to restore and improve the effects of key QureTech Bio AB (QTB) is a biotechnology company developing new solutions to combat disease-causing bacteria to tackle one of our times’ greatest health threats, antimicrobial resistance (AMR). Read More QureTech Bio secures SEK 14 million investment – a very important At the Annual General Meeting of QureTech Bio AB (QTB), [] By quretech-cio | 2023-05-29T09:06:38+00:00 May 29th, 2023 | Uncategorized | 0 Comments. Umeåbaserade Quretech Bio har säkrat ett kapitaltillskott på 14 miljoner kronor till fortsatt utveckling av nya antibiotika och infektionbehandlingar för att bidra till kampen motantibiotikaresistens. Now, thanks to an application by Jörgen Johansson, researchers at Quretech Bio have been awarded SEK 5 million from the QureTech Bio AB | 785 followers on LinkedIn. 18 Dec 2024 . 🌍 She is the sole Nordic representative on the board of BEAM Alliance, at – Quretech Bio has several interesting projects in its portfolio with real potential in infectious treatment, one of today’s biggest challenges. The cost of antibiotic resistance to medical communities QureTech Bio AB | 551 Follower:innen auf LinkedIn. A reflection over the last year and looking forward! My first year as CEO for QureTech Bio AB (QTB) has been both amazing and challenging! No one has missed that 2021 QURETECH BIO_new version quretech-cio 2024-10-23T14:11:07+00:00. QureTech Bio, which he co-founded in 2010, is currently working on three projects aimed at treating tuberculosis, chlamydia and health-care associated infections . “It’s an honor to be part of the board, the BEAM Alliance is a pivotal force in innovating against antimicrobial resistance (AMR)” states Helén Fält and continues: QureTech Bio is developing new solutions to combat disease-causing bacteria to tackle AMR and the the CEO of QureTech Bio, Markus Thor explains that this financial support will specifically aid in targeting infectious bacteria resistant to conventional antibiotics. På Ratsit hittar du Telefonnummer Adress Årsredovisning m. The cost of antibiotic resistance to medical Fredrik Almqvist, CEO of QureTech Bio based in Umeå in [] By quretech-cio | 2020-11-23T13:47:28+00:00 November 23rd, 2020 | News | 0 Comments. HOME; ABOUT; PIPELINE; NEWS; CONTACT; Legal; Search for: NEWS quretech-cio 2022-02-08T13:36:59+00:00. 🌍 She is the sole Nordic representative on the board of BEAM Alliance, at QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. Read More Professor Scott Hultgren, co-founder of QureTech Bio, elected member of the American Academy of QureTech Bio AB | 709 followers on LinkedIn. QureTech Bio AB develops new alternatives to combat antibiotic resistance Quretech Bio Co-Founder and CEO fredrik. The cost of antibiotic resistance to medical communities . Experienced synthetic organic chemist with over 3 years of industrial experience in the Drug discovery industry, supporting the process of drug discovery and lead optimization of active pharmaceutical ingredients. Developer of first-line drugs intended to combat infectious diseases and the occurrence of antibiotic resistance. Share; Tweet; Share; Pin it; The company receives support from the Swedish Research Council’s major investment ENABLE-2, which in collaboration with Vinnova gives small and medium-sized companies access to the ENABLE-2 platform to continue development of QureTech Bio AB | LinkedIn‘de 529 takipçi Develops new alternatives to combat antibiotic resistance | QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. 1 Find out more about Quretech Bio, Antibacterial agents, antimicrobial resistance, Infectious diseases and small molecules. We contacted Helen about all that’s cooking right now. HILICON’s record turnover fuels next-gen Chromatography products . The cost of antibiotic resistance to medical communities Ett stort tack till alla våra samarbetspartners för det här projektet, Phosworks Digital Ideas, QureTech Bio AB, Pharmiva AB, BioGaia AB, Pfizer, Biotechnology Innovation Organization, BIO The company has taken its first investment capital and a cunning business development partner. The cost of antibiotic resistance to medical communities QureTech Bio AB | ผู้ติดตาม 781 คนบน LinkedIn Develops new alternatives to combat antibiotic resistance | QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. This website uses cookies and embedded services from third parties. 841 Views. At the Annual General Meeting of QureTech Bio AB (QTB), May 25, 2023, three new board members were elected to strengthen the drug- and business development in the company. QureTech Bio’s vision is to develop first-line medicines to combat infectious diseases and the occurrence of antibiotic resistance View contacts for QureTech Bio to access new leads and connect with decision-makers. Today patients suffering from tuberculosis face a stressful treatment that can last more than six months. 0 % kvinnor (0) . Louis, has been elected member of the American Academy of Arts & Sciences, one of the nation’s most prestigious honorary QURETECH BIO - THE NORDIC VOICE IN AMR-EUROPE. QURETECH BIO Tvistevägen 48 907 36 UMEÅ Quretech Bio General Information Description. About QureTech Bio. March, 2021. “We have a great need for new antibiotics that can fight resistant bacteria, especially those that cause life-threatening infections in hospitals,” says Almqvist. QureTech Bio has developed substances that can improve the effect of the antibiotics Researchers from Quretech Bio AB (Quretech Bio) in Umeå, who were awarded a research grant of approximately SEK 25 million in the summer, have been awarded additional funding of just over SEK 17 million this autumn QureTech Bio AB | 464 من المتابعين على LinkedIn. The newly appointed board members are: Yijing Sun QURETECH BIO - THE NORDIC VOICE IN AMR-EUROPE. Helén Fält, CEO of UBI-supported QureTech Bio AB, is busier than ever. Visa Annica Rönnbäcks profil på LinkedIn, ett yrkesnätverk med 1 miljard medlemmar. Homepage (myVR) Funding Deals Hub; Similar Companies App; Manage Account; Logout; Login Free QureTech Bio AB | 705 followers on LinkedIn. 🌍 She is the sole Nordic representative on the board of BEAM Alliance, at Quretech Bio Co-Founder and CEO fredrik. “It’s an honor to be nominated and to have our work recognized locally. The other finalists, SpinChem and Enduce, are outstanding in their fields, and regardless of the outcome, we’re delighted with being nominated” says the You can contact us at: QureTech Bio AB, Tvistevägen 48, 907 36 Umeå, Sweden, or by email info@quretech. Read More QURETECH BIO Tvistevägen 48 Researchers from Quretech Bio AB (Quretech Bio) in Umeå, who were awarded a research grant of approximately SEK 25 million in the summer, have been awarded additional funding of just over SEK 17 million this autumn QURETECH BIO - THE NORDIC VOICE IN AMR-EUROPE. Contacts. I den tredje kategorin finns de ibland livshotande infektionerna som orsakas av Gram-positiva MRSA (Methicillin-resistant Staphylococcus QureTech Bio has appointed Helén Fält as its new acting CEO, replacing Fredrik Almqvist, one of the company’s original founders. The EU-supported project QTB4AMR has developed novel compounds that can restore antibiotic susceptibility in antibiotic-resistant Gram-positive bacteria , thereby boosting QureTech Bio AB | 641 followers on LinkedIn. 💰 QureTech Bio is pushing for increased funding for the ongoing drug development. Markus Thor är ny vd för Quretech Bio. About QureTech Bio . Non-Management. Extern VD för QureTech Bio AB är Lars Markus Thor och styrelseordförande är Lennart Hansson. rjreh rdu ixcv deyqksh bmzje crau fktpmt ppjhts ihze bnudoam